Indian vaccine innovation: The case of Shantha Biotechnics

Globalization and Health

Volumn 7, Issue , 2011, Pages

  Chakma, Justin ^a   Masum, Hassan ^a   Perampaladas, Kumar ^a   Heys, Jennifer ^a   Singer, Peter A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

CHILD HEALTH; DEVELOPING WORLD; HEALTH SERVICES; HEPATITIS; PUBLIC HEALTH; VACCINATION; VACCINE; WORLD HEALTH ORGANIZATION;

ARTICLE; BIOTECHNOLOGICAL PRODUCTION; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; DRUG MANUFACTURE; HEALTH CARE INDUSTRY; HEALTH CARE NEED; HEPATITIS B; HUMAN; INDIAN; PRIORITY JOURNAL;

INDIA;

EID: 79954596364     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/1744-8603-7-9     Document Type: Article

References (60)

1. Binder G, Bashe P. Science Lessons: What the Business of Biotech Taught Me About Management. 2008, Cambridge: Harvard Business School Press.
2. Feldman M, Colaianni A, Liu K. Commercializing Cohen-Boyer 1980-1997. 2005, Kauffman Foundation.
3. Pisano G. Science Business: The Promise, the Reality, and the Future of Biotech. 2006, Cambridge: Harvard Business School Press.
4. Kumar NK, Quach U, Thorsteinsdottir H, Somsekhar H, Daar AS, Singer PA. Indian biotechnology - rapidly evolving and industry led. Nature Biotechnology 2004, 22(Suppl):DC31-6.
5. Maiti R, Rahavendra M. Clinical trials in India. Pharmacological Research 2007, 56(1):1-10. 10.1016/j.phrs.2007.02.004, 17391981.
6. Frew SE, Rezaie R, Sammut SM, Ray M, Daar AS, Singer PA. India's health biotech sector at a crossroads. Nature Biotechnology 2007, 25(4):403-417. 10.1038/nbt0407-403, 17420744.
7. Ramani SV. Who is interested in biotech? R&D strategies, knowledge base and market sales of Indian biopharmaceutical firms. Research Policy 2002, 31(3):381-398.
8. Sanofi Pasteur. , http://en.sanofi-aventis.com/binaries/20090727_shantha_control_en_tcm28-25746.pdf
9. Torsoli A. Sanofi agrees to take control of India's Shantha. , http://www.bloomberg.com/apps/news?pid=20601202&sid=aLamsVEC7AUA
10. Yin RK. Case Study Research: Design and Methods. 2003,
11. Al-Bader S, Masum H, Simiyu K, Daar AS, Singer PA. Science-based health innovation in sub-Saharan Africa. BMC Int Health Hum Rights 2010, 10(Suppl 1):S1. 10.1186/1472-698X-10-S1-S1, 3001606, 21144069.
12. Chakma J, Masum H, Perampaladas K, Heys J, Singer PA. India's Billion Dollar Biotech. Nature Biotechnology 2010, 28(8):783. 10.1038/nbt0810-783, 20697399.
13. World Health Organization Country Office for India Introducing Hepatitis B Under Universal Immunization: Frequently Asked Questions. World Health Organization Country Office for India., http://www.whoindia.org/EN/Section6/Section8_26.htm
14. Frost LJ, Reich MR. Access: How do good health technologies get to poor people in poor countries?. 2009, Cambridge: Harvard University Press.
15. UNICEF. , http://www.unicef.org/infobycountry/india_statistics.html
16. Shekhar C. Pischia Power: India's Biotech Industry Puts Unconventional Yeast to Work. Chemistry & Biology 2008, 15(3):201-202. 10.1016/j.chembiol.2008.03.002, 18355715.
17. Revathi C. Meeting of Commission of Intellectual Property Rights, Innovation & Public Health. , http://www.who.int/intellectualproperty/events/en/Revathi.pdf
18. Financial Express Shantha Biotech Plans To Raise $25 Million. Financial Express., http://www.financialexpress.com/news/shantha-biotech-plans-to-raise-25-million/52289
19. Acharya T, Kumar NK, Muthuswamy V, Daar AS, Singer PA. "Harnessing genomics to improve health in India" - an executive course to support genomics policy. Health Res Policy Syst 2004, 2(1):1. 10.1186/1478-4505-2-1, 434533, 15151698.
20. Government of India. , http://india.gov.in/citizen/health/hepatitis.php
21. Bloomberg News Sanofi Agrees to take Control of India's Shantha. Bloomberg News., http://www.bloomberg.com/apps/news?pid=20601091&sid=aHyZdTO4KkGc
22. World Intellectual Property Organization A Process for the Production of Human Interferon Alpha from Genetically Engineered Yeast. World Intellectual Property Organization., http://www.wipo.int/pctdb/en/wo.jsp?wo=2001068827
23. Natesh S, Bhan MK. Biotechnology sector in India: strengths, limitations, remedies and outlook. Current Science 2009, 2(25):157-169.
24. Business Standard Shantha Bio launches its 4th r-DNA product. Business Standard., http://www.business-standard.com/india/news/shantha-bio-launches-its-4th-r-dna-product/199864/
25. World Health Organization. , http://www.who.int/immunization_standards/vaccine_quality/pq_suppliers/en
26. Shantha Biotech Research & Development: Pipeline. Shantha Biotech., http://www.shanthabiotech.com/pipe_line.htm
27. Shantha Biotech Corporate Presentation. Shantha Biotech., http://www.shanthabiotech.com/corporate_film/presentation.pps
28. Shantha Biotech Research & Development. Shantha Biotech., http://www.shanthabiotech.com/rd_overview.htm
29. PATH. , http://www.path.org/projects/rotavirus_vaccine_projects.php
30. Centre for Cellular & Molecular Biology. , http://www.ccmb.res.in/
31. Pantulu CC. Shantha Biotechnics accuses SmithKline of indulging in unfair practices. Financial Express 1998, http://www.financialexpress.com/old/fe/daily/19980520/14055184.html
32. Abraham P, Mistry FP, Bapat MR, Sharma G, Reddy GR, Prasad KSN, Ramanna V. Evaluation of a New Recombinant DNA Hepatitis B Vaccine (Shanvac-B). Vaccine 1999, 17:1125-1129. 10195623.
33. Motwani N. Biosimilars Jumpstart Biotech in India. Genetic Engineering & Biotechnology News 2007, 27(8). 21625884.
34. Department of Biotechnology, Ministry of Science and Technology, Government of India National Biotechnology Development Strategy: Key Elements. Delhi 2007, Department of Biotechnology, Ministry of Science and Technology, Government of India.
35. Rao SR. Indian biotechnology developments in public and private sectors - status and opportunities. Asian Biotechnology and Development Review 2007,
36. The Economist Big drug firms embrace generics: friends for life. 2009, The Economist., http://www.economist.com/businessfinance/displaystory.cfm?story_id=14177559
37. International Vaccine Institute. , http://www.ivi.org/program/tr_domi_cholera.html
38. International Vaccine Institute World's first low-cost cholera vaccine licensed in India. 2009, International Vaccine Institute., http://www.ivi.org/event_news/news_view_1.asp?enid=95
39. Pharmafocus Sanofi buys Indian vaccine firm. 2009, Pharmafocus., http://www.pharmafocus.com/cda/focusH/1,2109,21-0-0-JUL_2009-focus_news_detail-0-493030,00.html
40. Margolis HS. Pediatric Dengue Vaccine in the Americas. 2008, New Orleans., http://www.cctrhib.org/Margolis_-_ASTMH_08.pdf
41. Shantha Biotech. , http://www.shanthabiotech.com/news_9.htm
42. Sanofi-Aventis. , http://www.shanthabiotech.com/Shantha_UN%20Order-Sep09.pdf
43. Martino M. Rumor: GSK close to deal for Shantha Biotech. 2009, http://www.fiercebiotech.com/story/rumor-gsk-close-deal-shantha-biotech/2009-05-28
44. Prahalad CK. The fortune at the bottom of the pyramid: eradicating poverty through profits. 2004, Philadelphia: Wharton School Publishing.
45. Hammond AL, Kramer WJ, Katz RS, Tran JT, Walker C. The Next 4 Billion: Market Size and Business Strategy at the Base of the Pyramid. 2007, Washington DC: World Bank Group.
46. Patel P, D'Souza R. Uncovering Knowledge Structures of Venture Capital Investment Decision Making. 2008, Washington: The Office of Advocacy of the U.S. Small Business Administration.
47. Jadhav SS, Gautam M, Gairola S. Emerging markets & emerging needs: developing countries vaccine manufacturers' perspective & its current status. Biologicals 2009, 165-168.
48. Intel. , http://www.intel.com/technology/tick-tock/index.htm
49. Chaturvedi K, Chataway J. Strategic integration of knowledge in Indian pharmaceutical firms: creating competencies for innovation. International Journal of Business Innovation and Research 2006, 1(1-2):27-50.
50. Crabtree P. An East-West Team. San Diego Union-Tribune 2005, http://legacy.signonsandiego.com/uniontrib/20050225/news_1b25shantha.html
51. Maiti R, Raghavendra M. Clinical trials in India. Pharmacological Research 2007, 56:1-10. 10.1016/j.phrs.2007.02.004, 17391981.
52. Chakma J, Calcagno JL, Behbahani A, Mojtahedian S. Is it Virtuous to be Virtual? The VC Viewpoint. Nature Biotechnology 2009, 27(10):886-888. 10.1038/nbt1009-886, 19816436.
53. Milstien JB, Kaddar M. The role of emerging manufacturers in access to innovative vaccines of public health importance. Vaccine 2010, 2115-2121.
54. Frew SE, Kettler HE, Singer PA. The Indian and Chinese Health Biotechnology Industries: Potential Champions of Global Health?. Health Affairs 2008, 27(4):1029-1041. 10.1377/hlthaff.27.4.1029, 18607038.
55. Sundaramoorthy S, Bindu YC, Mehdiratta R, Saberwal G. The US patent holdings of homegrown Indian biotech and pharma companies. Current Science 2009, 96(2):252-259.
56. Nauriyal DK. TRIPS-Compliant New Patents Act and Indian Pharmaceutical Sector Directions in Strategy and R&D. Indian Journal of Economics & Business 2007, 1-18. Special Issue China & India, 12290259.
57. Kettler HE, Modi R. Building local research and development capacity for the prevention and cure of neglected disease and cure of neglected diseases: the case of India. Bull. World Health Organ 2001, 79(8):742-747. 2566488, 11545331.
58. Milstien J, Kaddar M. Managing the effect of TRIPS on availability of priority vaccines. Bulletin of the World Health Organization 2006, 84:360-365. 10.2471/BLT.05.028431, 2627354, 16710544.
59. Milstien J. Challenges and potential solutions to innovative vaccine development for developing countries. Proceedia in Vaccinology 2009, 1:183-188.
60. Rezaie R, Singer PA. Global health or global wealth?. Nature Biotechnology 2010, 28(9):907-909. 10.1038/nbt0910-907, 20829824.